Substituted thieno[2,3-d]pyrimidines as AMPA modulators
View Patent ↗The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and learning and memory disorders such as Alzheimer's disease.
1. A heterocyclic compound according to formula I
wherein
L is (CH 2 ) m , wherein m is 1 or 2;
R 1 is C 1-4 alkyl, C 3-5 cycloalkyl, C 1-4 alkyloxy, halogen or CN, said C 1-4 alkyl, C 3-5 cycloalkyl and C 1-4 alkyloxy being optionally substituted with one or more halogens;
R 2 is C 1-4 alkyl, C 3-5 cycloalkyl or C 1-4 alkyloxy, said C 1-4 alkyl, C 3-5 cycloalkyl and C 1-4 alkyloxy being substituted with a substituent selected from OH, C 1-4 alkyloxy and NR 9 R 10 ;
X 1 , X 2 or X 3 are independently N or CR 3 , wherein R 3 is H or methyl;
Y 1 is NR 4 , wherein R 4 is H or C 1-4 alkyl;
Y 2 is CR 5 , wherein R 5 is H, C 1-4 alkyl, C 3-8 cycloalkyl or C 6-10 aryl;
R 6 is H, C 1-4 alkyl or C 3-5 cycloalkyl;
Y 3 is S;
Y 4 is N;
R 9 and R 10 are independently H or C 1-4 alkyl optionally substituted with a 5-9 membered heteroaryl ring system comprising 1-2 heteroatoms selected from O, S and N, or R 9 and R 10 together with the N to which they are bonded form a 4-6 membered saturated or unsaturated heterocyclic ring optionally comprising another heteroatom selected from O, S and N;
or a pharmaceutically acceptable salt thereof.
2. The heterocyclic compound according to claim 1 , wherein R 1 is CF 3 .
3. The heterocyclic compound according to claim 1 , wherein R 2 is methyl optionally substituted with hydroxy or NR 9 R 10 .
4. The heterocyclic compound according to claim 1 , wherein X 1 and X 2 are N and X 3 is CH.
5. The heterocyclic compound according to claim 1 , wherein Y 1 is NR 4 and R 4 is H or methyl.
6. The heterocyclic compound according to claim 1 , wherein Y 2 is CR 5 and R 5 is H or methyl.
7. The heterocyclic compound according to claim 1 , wherein R 6 is H or methyl.
8. The heterocyclic compound according to claim 1 , wherein m is 1.
9. A heterocyclic compound selected from:
or a pharmaceutically acceptable salt thereof.
10. The heterocyclic compound of claim 9 , wherein the heterocyclic derivative is
or a pharmaceutically acceptable salt thereof.
11. The heterocyclic compound of claim 9 , wherein the heterocyclic derivative is
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a heterocyclic compound or a pharmaceutically acceptable salt thereof according to claim 1 in admixture with one or more pharmaceutically acceptable auxiliaries.
13. A pharmaceutical composition according to claim 12 , wherein the heterocyclic compound is selected from the group consisting of
or a pharmaceutically acceptable salt thereof, in admixture with one or more pharmaceutically acceptable auxiliaries.
14. The pharmaceutical composition according to claim 13 , wherein the heterocyclic compound is
or a pharmaceutically acceptable salt thereof.
15. The pharmaceutical composition according to claim 13 , wherein the heterocyclic compound is
or a pharmaceutically acceptable salt thereof.